Keywords:
surufatinib, surufatinib’s R&D Progress, Mechanism of Action for surufatinib, drug target for surufatinib.
Description:
This article summarized the latest R&D progress of surufatinib, the Mechanism of Action for surufatinib, and the drug target R&D trends for surufatinib.
Text:
surufatinib‘s R&D Progress
Surufatinib is a small molecule drug that targets CSF-1R, FGFR1, and VEGFR. It has shown potential in treating various therapeutic areas including neoplasms, digestive system disorders, urogenital diseases, endocrinology and metabolic disease, and respiratory diseases. The drug has been indicated for the treatment of pancreatic islet cell tumors, neuroendocrine tumors, neuroendocrine carcinoma, solid tumors, bile duct neoplasms, small cell lung cancer, colorectal cancer, thyroid cancer, neoplasms, biliary tract neoplasms, sarcoma, kidney diseases, endometrial carcinoma, esophageal squamous cell carcinoma, and stomach cancer.
Surufatinib was developed by Hutchison MediPharma Ltd., an originator organization in the pharmaceutical industry. It has reached the highest phase of development, with approvals obtained both globally and in China. The drug was approved for patients in China in December 2020.
In terms of regulation, Surufatinib has been granted priority review, fast track designation, and orphan drug status. These regulatory designations highlight the potential benefits and urgency of the drug in addressing unmet medical needs.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for surufatinib: CSF-1R antagonists FGFR1 antagonists VEGFR antagonists
CSF-1R antagonists are drugs that specifically target and inhibit the activity of the colony-stimulating factor 1 receptor (CSF-1R). The CSF-1R is a protein receptor found on the surface of certain cells, including immune cells and cancer cells. By blocking the interaction between CSF-1R and its ligands, these antagonists can interfere with the signaling pathways involved in cell growth, survival, and immune response regulation. This can be beneficial in the treatment of diseases where excessive activation of CSF-1R is implicated, such as certain types of cancer and autoimmune disorders.
FGFR1 antagonists, on the other hand, target and inhibit the fibroblast growth factor receptor 1 (FGFR1). FGFR1 is a receptor protein that plays a crucial role in cell growth, tissue development, and wound healing. By blocking the activity of FGFR1, these antagonists can interfere with the signaling pathways involved in cell proliferation and angiogenesis (the formation of new blood vessels). This can be useful in the treatment of diseases where abnormal activation of FGFR1 is involved, such as certain types of cancer and certain genetic disorders.
VEGFR antagonists specifically target and inhibit the activity of the vascular endothelial growth factor receptor (VEGFR). VEGFR is a receptor protein found on the surface of endothelial cells, which line the blood vessels. By blocking the interaction between VEGFR and its ligands, these antagonists can disrupt the signaling pathways involved in angiogenesis and vascular permeability. This can be beneficial in the treatment of diseases where excessive angiogenesis is problematic, such as certain types of cancer and age-related macular degeneration.
In summary, CSF-1R antagonists, FGFR1 antagonists, and VEGFR antagonists are all types of drugs that target specific receptors involved in cell signaling pathways. They work by inhibiting the activity of these receptors, which can have therapeutic benefits in various diseases.
Drug Target R&D Trends for surufatinib
CSF-1R, FGFR1, and VEGFR are crucial receptors involved in various physiological processes in the human body. CSF-1R, also known as colony-stimulating factor 1 receptor, plays a vital role in regulating the development and function of macrophages, a type of immune cell. FGFR1, or fibroblast growth factor receptor 1, is involved in cell growth, tissue repair, and angiogenesis. VEGFR, or vascular endothelial growth factor receptor, is essential for the formation of new blood vessels and plays a critical role in processes like wound healing and embryonic development. Understanding the functions of these receptors is crucial for developing targeted therapies in the pharmaceutical industry.
According to Patsnap Synapse, as of 6 Sep 2023, there are a total of 4 CSF-1R + FGFR1 + VEGFR drugs worldwide, from 15 organizations, covering 39 indications, and conducting 458 clinical trials.
The analysis of the current competitive landscape and future development of target CSF-1R + FGFR1 + VEGFR reveals that multiple companies are actively involved in the research and development of drugs targeting this specific target. Bayer AG, Hutchison MediPharma Ltd., and HUTCHMED (China) Ltd. are among the companies with the highest stage of development. The indications for these drugs cover a wide range of cancers and tumors, indicating the potential for treating various types of cancer. Small molecule drugs are progressing rapidly, suggesting intense competition in the market. China, along with other countries such as the United States, European Union, and Japan, is actively developing drugs targeting CSF-1R + FGFR1 + VEGFR. The future development of this target holds promise for the treatment of cancer and offers opportunities for further research and innovation in the pharmaceutical industry.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
Overall, Surufatinib represents a promising advancement in the field of biomedicine. Its multi-target approach, targeting CSF-1R, FGFR1, and VEGFR, suggests a potential for improved efficacy in treating various diseases. The drug’s approval in China indicates its safety and efficacy profile, paving the way for potential approvals in other countries. The regulatory designations further emphasize the importance of Surufatinib in addressing critical medical conditions.
